Veracyte Decipher Prostate test predicts benefit of adding hormone therapy to radiation in Phase III trial analysis
VCYT•A retrospective analysis of the Phase III NRG/RTOG 0815 trial found the Decipher Prostate test identified intermediate-risk patients likely to benefit from adding short-term hormone therapy to radiation, while patients with low-risk genomic profiles showed little added benefit. Results will be presented at the ASTRO Annual Meeting on Sept. 29, 2026.
1. Trial analysis findings
Veracyte flagged new Decipher Prostate test data from a retrospective analysis of the Phase III NRG/RTOG 0815 trial. The study found the test identified intermediate-risk patients likely to gain meaningful benefit from adding short-term hormone therapy to radiation.
2. Low-risk profiles
Patients with low-risk genomic profiles showed little added benefit, supporting potential treatment de-intensification to avoid hormone-therapy side effects. The findings broaden Decipher’s role from risk assessment to treatment selection, reinforcing its strategic value in the intermediate-risk care pathway.
3. Presentation date
Results will be presented at the ASTRO Annual Meeting on Sept. 29, 2026.
